Cancer can be cured.

If detected early.

Exosomics envisions a world in which a simple blood draw will be sufficient for early diagnosis, easier monitoring and ultimately better patient outcomes.

Our mission is to develop and commercialize a new generation of tests for cancer screening and liquid biopsy, based on analysis of circulating extracellular vesicles and exosomes.

The company offers a wide range of proprietary solutions for cancer screening and liquid biopsy, suitable for research use and clinical diagnostics.

Exosomics’ APPROACH



Our approach is based on the detection of  cancer hallmarks shuttled by tumor exosomes as early sentinels of tumor occurrence.


We believe that the input material in any diagnostic test is a key element for the success of the test itself. We develop solutions for the extraction of tumor-derived material from biofluids such as blood and urine.


Our solutions enable early cancer detection, better tumor staging, prognostics and monitoring from a simple blood draw. This brings many advantages compared to current tissue biopsy approaches.


Our tests are simple, reliable, and cost-effective. We offer custom scalable solutions for the selective isolation of exosomes and the characterization of their content.


Patients First, Relentless Optimism, Caring with Honesty, Teamwork, Our Clients are Our Partners